Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis

Valeria Studer, Silvia Rossi, Caterina Motta, Fabio Buttari, Diego Centonze

Research output: Contribution to journalArticle

Abstract

B cells and/or the enhanced inflammatory milieu in the subarachnoid space are supposed to have a role in cortical pathology of progressive multiple sclerosis (PMS). The efficacy of intravenous rituximab to deplete circulating B cells is remarkable in MS, and its intrathecal delivery could target compartmentalized inflammation in PMS. We describe the central and peripheral effects of repeated intrathecal rituximab administrations in a patient with severe PMS. Peripheral CD20. + B cells were reduced, while oligoclonal bands were unaffected. Several central proinflammatory cytokines, and markers of neurodegeneration were markedly reduced. Central B cells modulation should be investigated in PMS.

Original languageEnglish
Pages (from-to)229-231
Number of pages3
JournalJournal of Neuroimmunology
Volume276
Issue number1-2
DOIs
Publication statusPublished - Nov 15 2014

Keywords

  • B lymphocytes
  • CD20
  • Neurodegeneration

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis'. Together they form a unique fingerprint.

  • Cite this